Boyce Sarah 4
4 · Avidity Biosciences, Inc. · Filed Sep 5, 2025
Insider Transaction Report
Form 4
Boyce Sarah
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2025-09-05$1.24/sh+50,000$62,000→ 355,871 total - Sale
Common Stock
2025-09-05$49.95/sh−50,000$2,497,435→ 305,871 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-05−50,000→ 1,022,015 totalExercise: $1.24Exp: 2029-12-17→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person.
- [F2]This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.76 to $50.12. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option award is fully vested and exercisable as of the date hereof.